This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Egrifta

Theratechnologies Inc.

Drug Names(s): ThGRF, TH9507, GHRH1-44, tesamorelin acetate

Description: ThGRF 1-44 peptide is a growth hormone-releasing factor analogue. ThGRF increases endogenous secretion of GH in a pulsatile fashion, as it respects the negative biofeedback of somatostatin.

Deal Structure: Theratechnologies and Sakai Chemical Industry
In February 2002, Theratechnologies and Sakai Chemical Industry entered into a licensing agreement for the development and marketing of Theratechnologies' ThGRF peptide (TH9507) in Japan in the hip fracture indication. The agreement also includes an option to develop three other indications currently targeted by Theratechnologies. The total deal value, including upfront payments and milestones, if all four indications are developed, will amount to US $ 36 M (CAN $ 57 M). Theratechnologies will also receive double-digit royalties and performance milestones based on future product sales.

Under the agreement, in addition to the hip fracture indication, Theratechnologies grants Sakai exclusive rights to co-develop and market the TH9507 technology in Japan in chronic obstructive pulmonary disease (COPD), sleep disorders and immune dysfunction indications as well as other indications which may be targeted by Theratechnologies in...See full deal structure in Biomedtracker

Partners: Bachem Merck KGaA AOP Orphan Pharmaceuticals AG BL&H Co., Ltd. Praxis Pharmaceutical, S.A.


Egrifta News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug